

New Zealand standardised oral formulation batch sheet

Allopurinol suspension 20 mg/mL (60 mL)										
Patient's name			Storage cond	tion	In a	In a refrigerator		At room temperature		
NHI			Temperature		2-8°C			≤ 25°C		
Date compounded	Date compounded		Shelf life		30 days			30 days		
Batch number	atch number		Recommended storage					May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided		
Ingredients required	and formula:				ı					
Ingredient	Supplier	Batch number	Expiry date		ndard Quantity mula dispensed		Dis	spensed	Checked by	
Allopurinol 300 mg tablets				4	tablets					
Ora-Blend®	Perrigo			to	60 mL					
OR							ı			
Ora-Plus®	Perrigo				30 mL					
Ora-Sweet®	Perrigo				30 mL					
Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? Yes										
Calculations performed by										
Calculations checked by (pharmacist)										
Area cleared for processing by										
Instructions to compound suspension:										
1. If Ora-Blend® unavailable: Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.										
2. Crush tablets in mortar to a fine powder.										
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.										
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.										
5. Make up to the final volume and mix well.										
6. Label and package product appropriately.										
Labels										
Attach product label	and auxiliary la	bels:						Label	checked by	



New Zealand standardised oral formulation batch sheet

Allopurinol suspension 20 mg/mL (60 mL)

			8,= (00	-,					
Final yield		_ mL	Checked by						
Final appearance of produ	rct Thick white sus	Thick white suspension.							
Container	Amber plastic r	Amber plastic mission bottle/ amber glass.							
Compounded by	Name:	Sig	nature:	Date:					
Final check and product re	Name:	Sig	nature:	Date:					
Special instructions: 1. Shake well before use. 2. Store in a refrigerator. References: 1. Allen LV, Jr., Erickson MA, 3rd. Am J Health Syst Pharm, 1996; 53(16): 1944-9. 2. Allen LV, Jr., Erickson MA, 3rd. Secundum Artem; 5(4). 3. Polonini HC, Loures S, de Araujo EP, et al. Int J Pharm Compd, 2016; 20(5): 426-434.									
Prepared by New Zealand Compounding Working Group									
Approved by Medication Safety Expert Advisory Group of Health Quality and Safety Commission									
Hosted by	•	tical Society of New Zealand ormulations in the Practice Support section of the PSNZ website							
Version number	3.0	Version a	Version approval date 17/07/19						

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.

01/08/21

Document review due